Question Number: 250
PDR Number: SQ22-000620
Date Submitted: 21/11/2022
Department or Body: Department of Health
One significant advantage of mRNA vaccines is that they use the existing translational machinery of the cell and other cytosolic components to produce a properly folded and fully functional protein from each injected mRNA (https://pubmed.ncbi.nlm.nih.gov/33907508/). The sequence of the mRNA of the S protein in the vaccine ensures the transport of mRNA to the endoplasmic reticulum (ER) for translation by ER ribosomes. The vaccine mRNA syntax starts with a cap followed by 5’ untranslated region. The 5’-untranslated region is the ribosome binding site. This sequence is followed by S glycoprotein signal peptide sequence, which is a codon optimized signal peptide enabling the S protein to be transported to the ER for further processing (e.g. folding). The mRNA is subsequently degraded within the cell by ribonucleases.